Valdecoxib NEW
| Price | $59 | $90 | $196 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: Valdecoxib | CAS No.: 181695-72-7 |
| Purity: 99.89% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | Valdecoxib |
| Description | Valdecoxib (SC 65872) is a prescription drug used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is classified as a nonsteroidal anti-inflammatory drug, or NSAID, and should not be taken by anyone allergic to these types of medications. |
| In vitro | Valdecoxib demonstrates significant efficacy in acute and chronic inflammation models in rats, with ED50 values of 0.06 mg/kg for carrageenan air-pouch inflammation, 5.9 mg/kg for paw edema, and 0.03 mg/kg for nonspecific arthritis. When administered alone, valdecoxib shows slow absorption in vivo, achieving a maximum inhibition of 16% in edema at 3 hours post-administration. In contrast, the valdecoxib complexes VALD-βCd and VALD-SBE7βCd exhibit high absorption rates, suppressing over 50% of edema within 1 hour, and achieving a maximum inhibition of 66% at 3 hours. Orally administered valdecoxib inhibits carrageenan-induced rat paw edema with an ED50 value of 10.2 mg/kg. In a rat model of nonspecific arthritis, oral valdecoxib shows chronic anti-inflammatory activity, with an ED50 of 0.032 mg/kg/day. Valdecoxib also inhibits prostaglandin production at the inflammation site in rats with carrageenan air-pouch inflammation when administered orally, with an ED50 value of 0.02 mg/kg. |
| In vivo | Valdecoxib inhibits the production of PGE2 in plasma induced by lipopolysaccharides (IC50: 0.89 μM) and suppresses the generation of TxB2 in plasma (IC50: 25.4 μM). It binds to COX-2 with a Ka of 1.1×10^5 M/s and exhibits a strong overall saturable binding affinity to COX-2 of 2.6 nM. After 15 minutes (DP15), valdecoxib has a solubility percentage of 10.5%, while its hydrophilic derivatives (VALD-βCd, VALD-HPβCd, and VALD-SBE7βCd complexes) display significantly increased solubility percentages of 50%, 91%, and 93%, respectively. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 60 mg/mL (190.86 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.36 mM), Sonication is recommended. |
| Keywords | Valdecoxib | SC-65872 | SC65872 | Inhibitor | inhibit | Cyclooxygenase | COX-2 | COX |
| Inhibitors Related | Sucrose | Aceglutamide | Nicotinamide riboside malate | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Malic acid | Glycerol | Thymidine | Corn starch | Trometamol | Gluconate Calcium | DL-Lysine |
| Related Compound Libraries | Highly Selective Inhibitor Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-07-09 | ||
| $59.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-04-21 | |
| $10.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2026-03-20 | ||
| $1.10 |
VIP6Y
|
Dideu Industries Group Limited
|
2025-11-18 | |
| $59.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-05-01 | |
| $10.00 |
Hebei Ganmiao New material Technology Co., LTD
|
2024-08-20 | ||
| $1.00 |
Guangzhou Biocar Biotechnology Co.,Ltd.
|
2022-12-29 | ||
| $10.00 |
Hebei Zhanyao Biotechnology Co. Ltd
|
2021-11-11 | ||
| $15.00 |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-13 | ||
|
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-02-26 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY